CD123表达与儿童急性髓系白血病高危疾病特征相关:来自儿童肿瘤协作组的报告
在儿童肿瘤协作组AAML1031 III期试验(NCT01371981)中,对1040例初诊儿童急性髓系白血病患者的诊断骨髓标本进行CD123蛋白表达的前瞻性多维流式细胞术免疫表型分析。CD123最高表达四分位(Q4)患者的高危KMT2A重排和FLT3-ITD突变患病率更高,低危t(8;21)、inv(16)和CEBPA突变患病率更低(均P < .001)。Q4患者较Q1-3患者复发风险更高(53% vs 39%,P < .001)、无事件生存率更低(49% vs 69%,P < .001)、总生存率更低(32% vs 50%,P < .001)。
要点
- CD123最高表达四分位(Q4)与高危KMT2A重排和FLT3-ITD突变患病率更高相关(均P < .001)。
- Q4患者较Q1-3患者复发风险更高(53% vs 39%,P < .001),无事件生存率更低(49% vs 69%,P < .001),总生存率更低(32% vs 50%,P < .001)。
- CD123在多变量Cox回归分析中纳入所有已知当代高危细胞遗传学和分子标志物后仍保持对结局的独立显著性。
核心结论
- CD123与儿童急性髓系白血病疾病相关的细胞遗传学和分子改变强烈相关。
- CD123是一个关键生物标志物和有前景的免疫治疗靶点,因其在具有高危遗传改变和常规治疗临床结局较差的患者中普遍表达且富集。
研究设计与样本
- 儿童肿瘤协作组AAML1031 III期试验(NCT01371981)中统一治疗的初诊儿童急性髓系白血病患者队列。
- 对诊断骨髓标本(n = 1,040)中的白血病原始细胞,在中心临床实验室通过多维流式细胞术免疫表型分析前瞻性分析CD123蛋白表达。
- 根据白血病相关细胞遗传学和分子改变以及诱导后可测量残留病水平将患者分为低危或高危。
- 研究人群按CD123表达分为四分位(每组n = 260)进行分析。
主要发现
- CD123最高表达四分位(Q4)患者的高危KMT2A重排和FLT3-ITD突变患病率更高(均P < .001)。
- Q4患者的低危t(8;21)、inv(16)和CEBPA突变患病率更低(均P < .001)。
- CD123较低表达四分位(Q1-3)患者的复发风险、无事件生存率和总生存率相似。
- Q4患者较Q1-3患者复发风险显著更高(53% vs 39%,P < .001)。
- Q4患者较Q1-3患者无事件生存率更低(49% vs 69%,P < .001)和总生存率更低(32% vs 50%,P < .001)。
关键数值与推荐
- CD123在多变量Cox回归分析中纳入所有已知当代高危细胞遗传学和分子标志物后仍保持对结局的独立显著性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increased CD123 surface expression has been associated with high-risk disease characteristics in adult acute myeloid leukemia (AML), but has not been well-characterized in childhood AML. In this study, we defined CD123 expression and associated clinical characteristics in a uniformly treated cohort of pediatric patients with newly diagnosed AML enrolled on the Children's Oncology Group AAML1031 phase III trial (NCT01371981). MATERIALS AND METHODS: AML blasts within diagnostic bone marrow specimens (n = 1,040) were prospectively analyzed for CD123 protein expression by multidimensional flow cytometry immunophenotyping at a central clinical laboratory. Patients were stratified as low-risk or high-risk on the basis of (1) leukemia-associated cytogenetic and molecular alterations and (2) end-of-induction measurable residual disease levels. RESULTS: The study population was divided into CD123 expression-based quartiles (n = 260 each) for analysis. Those with highest CD123 expression (quartile 4 [Q4]) had higher prevalence of high-risk KMT2A rearrangements and FLT3-ITD mutations (P < .001 for both) and lower prevalence of low-risk t(8;21), inv(16), and CEBPA mutations (P < .001 for all). Patients in lower CD123 expression quartiles (Q1-3) had similar relapse risk, event-free survival, and overall survival. Conversely, Q4 patients had a significantly higher relapse risk (53% v 39%, P < .001), lower event-free survival (49% v 69%, P < .001), and lower overall survival (32% v 50%, P < .001) in comparison with Q1-3 patients. CD123 maintained independent significance for outcomes when all known contemporary high-risk cytogenetic and molecular markers were incorporated into multivariable Cox regression analysis. CONCLUSION: CD123 is strongly associated with disease-relevant cytogenetic and molecular alterations in childhood AML. CD123 is a critical biomarker and promising immunotherapeutic target for children with relapsed or refractory AML, given its prevalent expression and enrichment in patients with high-risk genetic alterations and inferior clinical outcomes with conventional therapy.
引用
- Lamble AJ, Eidenschink Brodersen L, Alonzo TA, et al. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2021. PMID: 34855461. doi:10.1200/JCO.21.01595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。